At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
vandetanib +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating vandetanib, placebo, and 4 other interventions for Lip and Oral Cavity Squamous Cell Carcinoma and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartJan 2012
Primary CompletionJan 2019
Study CompletionJun 2019
TodayJul 2026
First PostedAug 11, 2011
Enrollment StartJan 1, 2012
Primary CompletionJan 1, 2019
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 14.9 years ago
Interventions
vandetanibdrug
Given PO
placeboother
Given PO
immunohistochemistry staining methodother
Correlative studies
laboratory biomarker analysisother
Correlative studies
biopsyprocedure
Correlative studies
pharmacological studyother
Correlative studies